NASDAQ:VIRI Virios Therapeutics (VIRI) Stock Forecast, Price & News $1.66 +0.17 (+11.41%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$1.48▼$1.6850-Day Range$0.35▼$1.7252-Week Range$0.22▼$9.11Volume734,952 shsAverage Volume1.93 million shsMarket Capitalization$13.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Virios Therapeutics (NASDAQ:VIRI) StockVirios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.Read More Receive VIRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VIRI Stock News HeadlinesMay 25, 2023 | finance.yahoo.comVirios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 16, 2023 | finance.yahoo.comVIRI: Ready to Move IMC-1 Into Phase 3 Program…June 6, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 16, 2023 | americanbankingnews.comVirios Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:VIRI)May 15, 2023 | finance.yahoo.comVirios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat FibromyalgiaMay 12, 2023 | marketwatch.com10-Q: VIRIOS THERAPEUTICS, INC.May 12, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Virios Therapeutics (VIRI)May 11, 2023 | benzinga.comRecap: Virios Therapeutics Q1 EarningsJune 6, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.May 11, 2023 | finance.yahoo.comVirios Therapeutics Announces First Quarter 2023 Financial ResultsMay 11, 2023 | americanbankingnews.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest UpdateMay 10, 2023 | msn.comEarnings Preview: Virios TherapeuticsMay 9, 2023 | americanbankingnews.comVirios Therapeutics (VIRI) Set to Announce Earnings on ThursdayMay 4, 2023 | finance.yahoo.comVirios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023April 25, 2023 | proactiveinvestors.comVirios Therapeutics stock doubles as fibromyalgia program moves forwardApril 25, 2023 | marketwatch.comVirios Therapeutics Shares Rise 52% After FDA Feedback for IMC-1April 25, 2023 | msn.comWhy Virios Therapeutics (VIRI) Stock Is SkyrocketingApril 25, 2023 | finance.yahoo.comVirios Therapeutics Shares Almost Double In Trading Session - Here's WhyApril 25, 2023 | investorplace.comWhy Is Virios Therapeutics (VIRI) Stock Up 92% Today?April 24, 2023 | finance.yahoo.comVirios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of FibromyalgiaMarch 30, 2023 | americanbankingnews.comShort Interest in Virios Therapeutics, Inc. (NASDAQ:VIRI) Increases By 52.5%March 27, 2023 | msn.comWhy Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 18, 2023 | benzinga.comWatching Virios Therapeutics; Zacks Small-Cap Research Sets $2 ValuationMarch 16, 2023 | finance.yahoo.comVIRI: Anticipating Update on IMC-1 Following ‘End-of-Phase 2’ Meeting with FDA…March 14, 2023 | finance.yahoo.comVirios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial ResultsMarch 14, 2023 | finance.yahoo.comVirios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial ResultsMarch 7, 2023 | finance.yahoo.comVirios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023See More Headlines VIRI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIRI Company Calendar Last Earnings3/14/2023Today6/05/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VIRI CUSIPN/A CIK1818844 Webwww.virios.com Phone866-620-8655FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.21% Return on Assets-112.74% Debt Debt-to-Equity RatioN/A Current Ratio11.88 Quick Ratio11.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book1.89Miscellaneous Outstanding Shares8,330,000Free Float6,672,000Market Cap$13.83 million OptionableNot Optionable Beta2.02 Key ExecutivesMr. Gregory Duncan (Age 57)Chairman & CEO Comp: $798.67kMr. Ralph D. Grosswald M.P.H. (Age 53)Sr. VP of Operations Comp: $274.69kDr. R. Michael Gendreau M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $459.9kMs. Angela Walsh (Age 55)CFO, SVP of Fin., Corp. Sec. & Treasurer Ms. Carol Duffy Ph.D.Chief Scientific AdvisorKey CompetitorsProcessa PharmaceuticalsNASDAQ:PCSAAkari TherapeuticsNASDAQ:AKTXIndaptus TherapeuticsNASDAQ:INDPInfinity PharmaceuticalsNASDAQ:INFIAeterna ZentarisNASDAQ:AEZSView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 125,311 shares on 5/16/2023Ownership: 1.943%Envestnet Asset Management Inc.Bought 11,467 shares on 5/11/2023Ownership: 1.449%Richard James WhitleySold 1,800 sharesTotal: $468.00 ($0.26/share)View All Insider TransactionsView All Institutional Transactions VIRI Stock - Frequently Asked Questions Should I buy or sell Virios Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Virios Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VIRI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIRI, but not buy additional shares or sell existing shares. View VIRI analyst ratings or view top-rated stocks. How have VIRI shares performed in 2023? Virios Therapeutics' stock was trading at $0.2360 at the beginning of the year. Since then, VIRI stock has increased by 603.4% and is now trading at $1.66. View the best growth stocks for 2023 here. Are investors shorting Virios Therapeutics? Virios Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 327,500 shares, a drop of 68.8% from the April 30th total of 1,050,000 shares. Based on an average daily trading volume, of 2,790,000 shares, the days-to-cover ratio is currently 0.1 days. View Virios Therapeutics' Short Interest. When is Virios Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our VIRI earnings forecast. How were Virios Therapeutics' earnings last quarter? Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings data on Tuesday, March, 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. When did Virios Therapeutics IPO? (VIRI) raised $30 million in an initial public offering on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. What is Virios Therapeutics' stock symbol? Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI." Who are Virios Therapeutics' major shareholders? Virios Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Susquehanna International Group LLP (1.94%) and Envestnet Asset Management Inc. (1.45%). Insiders that own company stock include Angela Walsh, Gregory Scott Duncan, Richard James Whitley and William Pridgen. View institutional ownership trends. How do I buy shares of Virios Therapeutics? Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Virios Therapeutics' stock price today? One share of VIRI stock can currently be purchased for approximately $1.66. How much money does Virios Therapeutics make? Virios Therapeutics (NASDAQ:VIRI) has a market capitalization of $13.83 million. The company earns $-12,250,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. How can I contact Virios Therapeutics? The official website for the company is www.virios.com. The company can be reached via phone at 866-620-8655 or via email at ir@virios.com. This page (NASDAQ:VIRI) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.